A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Phase of Trial: Phase I/II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs AG-019 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ActoBio Therapeutics
- 29 Oct 2018 According to ActoBio Therapeutics media release, company Doses First Patient in thi study.
- 29 Oct 2018 According to ActoBio Therapeutics media release,Status changed from planning to recruiting.
- 05 Apr 2018 New trial record